



# 2025 Specialty Qualifying Examination



Certification demonstrates to the public that a physician and medical specialist meets nationally recognized standards for education, knowledge, experience, and skills and maintains their certification through continuous learning and practice improvement in order to provide high quality care in a specific medical specialty. Once board certified, OB GYNs will be referred to as a Diplomate of the board and will be able to proudly display the ABOG Board-Certified badge.

This Bulletin, issued in September 2024, represents the official statement of the requirements in effect for the Specialty Qualifying Examination to be given on July 21, 2025.

All questions and inquiries can be submitted here [here](#).

## Disclaimers

- \*Gender Language
- \*Non-Discrimination and Fairness
- \*Candidate Responsibility
- \*Candidate Board Status

Revised October April 14, 2025

## TABLE OF CONTENTS

|  |    |
|--|----|
| 2025 QUALIFYING EXAMINATION                                    | 3  |
| Introduction   | 3  |
| Eligibility Requirements                                       | 3  |
| Residency Training Attestations                                | 5  |
| Application Process  | 6  |
| Fees and Deadlines   | 7  |
| Exam Content   | 7  |
| Exam Administration  | 8  |
| Results and Scoring  | 9  |
| APPENDIX A: DISCLAIMERS  | 10 |
| Gender Language  | 10 |
| Non-Discrimination and Fairness                                | 10 |
| Candidate Responsibility                                       | 10 |
| Candidate Board Status   | 11 |
| APPENDIX B: DISQUALIFICATION FROM THE QUALIFYING EXAMINATION   | 12 |
| APPENDIX C: REQUESTS FOR ACCOMMODATIONS                        | 13 |
| Candidate Disability   | 13 |
| Lactation Accommodations                                       | 14 |
| APPENDIX D: APPROVED ABBREVIATIONS FOR EXAMINATIONS            | 15 |
| APPENDIX E: SPECIALTY QUALIFYING EXAMINATION TOPICS            | 20 |
| Obstetrics   | 20 |
| Gynecology   | 21 |
| Office Practice  | 23 |
| Cross Content  | 25 |
| APPENDIX F: RESCORES, APPEALS, AND REQUESTS FOR RE-EXAMINATION | 26 |
| Rescores and Appeals   | 26 |
| Requests for Re-Examination                                    | 26 |

## 2025 QUALIFYING EXAMINATION

### Introduction



ABOG certification is a two-step process that is completely voluntary. The Qualifying Examination is the first of the two steps in ABOG's initial certification process. Each potential candidate is responsible for completing the application for the Qualifying Examination online at [www.abog.org](http://www.abog.org), submitting all required materials to ABOG at the time they are requested, and meeting all deadlines. ABOG will make the final decision concerning the applicant's admission to the examination after considering all circumstances affecting the application.

### Eligibility Requirements

1. It is not necessary to have a medical license to sit for the Qualifying Examination. However, if a medical license is held, it must be unrestricted without conditions (see Disqualification from the Qualifying Examination in [Appendix B](#) for further information.) An unrestricted medical license will be required to apply for the Certifying Examination.
2. All applicants must hold a Doctor of Medicine or Doctor of Osteopathic Medicine degree.
3. Residency Requirements:
  - a. Candidates for certification are required to complete 48 months of graduate medical education in an Obstetrics and Gynecology residency program(s) that is ACGME-accredited at the time of completion of training. Candidates who will complete their residency training after September 30, 2025, will not be allowed to sit for the 2025 Qualifying Examination.

Alternately, this requirement can be met by completing no fewer than 60 months in a clinical Obstetrics and Gynecology program(s) accredited by the Council of the Royal

College of Physicians and Surgeons of Canada (CRCPSC) no later than September 30, 2025. A minimum of 48 months of that training must be in Obstetrics and Gynecology. No credit for training outside of Canada may be counted toward meeting the 60-month training requirement.

Residents who complete 48 months in an AOA-accredited (American Osteopathic Association) program that achieves ACGME initial accreditation before their graduation are eligible to take the ABOG Qualifying Examination.

No credit will be given for residency training in programs accredited by any other organization, including ACGME-International.

If a resident's completion date changes and they will not complete their residency by September 30, 2025, they will not be eligible to take the Qualifying Examination in 2025. Any resident who takes the Qualifying Examination without completing residency by September 30, 2025, will have the results voided and will not receive a refund.

- b. Either the PGY3 or PGY4 year of a residency program must include the responsibilities of a chief (senior) resident in accordance with the description of the program as accredited by the ACGME. Residents who receive credit for time spent in a non-ACGME-accredited residency program must serve their senior year as a PGY4. (See Requirement 3.e. below.)
- c. When a resident's graduate education and clinical experience have been gained in more than one residency program, the satisfactory performance at the previous program(s) must first be verified before an application to take the Qualifying Examination will be made available for the resident to complete. Fewer than 6 months in any OB-GYN residency program will not count toward meeting the 48-month requirement.
- d. A resident who has a firm commitment to a position in an ACGME-accredited subspecialty fellowship may be allowed flexibility in their residency training program. To be eligible, ABOG and ACGME must receive a request from the residency Program Director before the start of the PGY3 year. If approved by ABOG and ACGME, the PGY3 year must be served as a senior resident, with duties and responsibilities similar to those of a PGY4 resident. If the resident satisfactorily completes the PGY3 senior resident year, they may begin the subspecialty fellowship in the PGY4 year. If the fellowship is not completed successfully, the physician must return to a residency program and complete a full 12-month PGY4 year.

Residents who have received credit for training (up to six months as detailed in Requirement 2.e. below) in a non-OB-GYN ACGME-accredited residency training program are not eligible for the flexibility option.

- e. Up to six months credit for previous training in a non-OB-GYN ACGME-accredited residency may be granted for residents entering an ACGME-accredited OB-GYN residency. The OB-GYN residency Program Director must request approval for a specific number of months, not to exceed six, before the start of the PGY4 year.

All leave time must be in accordance with the [ABOG Resident Leave Policy](#) outlined on the ABOG website. Extensions of training must have an educational plan for the continued training with specific educational and clinical experience goals and objectives to be achieved, including for the chief (senior) resident year. This educational plan must include a description of what training was missed, how the missed training is being attained, and a block diagram that covers the entire length of training. This plan must be submitted to ABOG for approval [here](#).

Foregoing vacation time or necessary sick leave to shorten the required 48 months of training or to “make up” for time lost due to sickness or other absence is not permitted.

Residents who have their residency extended may sit for the Qualifying Examination in July if they will have completed all 48 months by September 30 of the same year. The results of their examination will not be released until and unless the Program Director notifies ABOG that they have completed their residency by September 30. If a resident does not complete residency by September 30, the results of their examination will be voided. Additionally, if ABOG does not receive notification of residency completion from the Program Director by January 1, 2026, the results of the examination will be voided.

- f. Each resident is required to maintain a record of the number and type of obstetric and gynecologic procedures performed during residency to demonstrate the adequacy of their operative experience.

#### 4. Limitation of Eligibility

All candidates must achieve board certification in Obstetrics and Gynecology within eight years of the completion of their residency training. Physicians who fail to become certified within eight years will be required to complete a minimum of six months of supervised practice at a hospital affiliated with an ACGME-accredited training program to regain eligibility to apply for the Qualifying Examination. For additional information on regaining eligibility, please see the policy [here](#). Once the supervised practice is completed, the physician will have four years to become certified.

Fellowship training in any program other than an ABOG- or ACGME-accredited Complex Family Planning, Female Pelvic Medicine and Reconstructive Surgery/Urogynecology and Reconstructive Pelvic Surgery, Gynecologic Oncology, Maternal-Fetal Medicine, Reproductive Endocrinology and Infertility, or government fellowship program will not extend the 8-year limit.

Candidates must meet all of the requirements in the Bulletin for the year they are applying for the test. Candidates may be disqualified from taking the Qualifying Examination, due to ethical, moral, or professional misconduct. For more information, see [Appendix B](#).

## Residency Training Attestations

At the end of their training the resident will be expected to attest to the following:

1. Compliance with the [ABOG Professionalism, Professional Standing, and Professional Conduct Policy](#).
2. Met the educational objectives of their training program.
3. Have demonstrated the knowledge, skills, and behaviors necessary to enter autonomous practice.

The Program Director will attest to the residents' satisfactory performance, professionalism, competence, and successful completion of the required months of clinical experience. The Program Director is expected to sign on behalf of the program and not as an individual.

Results of the examination will not be released until all resident and Program Director attestations are complete.

A new attestation is not necessary for those candidates who have completed their residency training and sat for the Qualifying Examination in a prior year if an attestation has been previously received at ABOG.

## **Application Process**

A unique ABOG ID number is assigned to each resident when the Residency Program Manager enters their information into the ABOG Program Portal. Once the ABOG ID number is created, the system will send an email to the resident with their ABOG ID and temporary password. If the resident does not receive this email, they should contact the Certification Standards Department [here](#) to request this information. A resident must be logged in to their ABOG portal to access the Qualifying Exam application. Applications will be accepted online beginning January 3. Late fees will apply for applications received after February 14. The last day to apply for the Qualifying Examination is February 28. The examination fee must be paid in full by credit card at the time of the application. All fees are quoted and must be paid in US dollars.

An approval email will be sent to each applicant at the email address currently listed in the Profile Section of the applicant's personal ABOG portal when they are approved to take the Qualifying Examination.

Once a candidate is approved to take the ABOG Qualifying Examination, any questions about exam protocols and processes should be submitted [here](#).

The approval email will contain information for contacting a Pearson VUE Testing Center to schedule a seat for the examination. After the approval email from ABOG is received, the candidate must contact Pearson VUE to obtain a seat for the examination. Candidates are urged to obtain a seat as soon as possible after notification of approval to avoid long-distance travel to a site with an available seat. On April 25, the ABOG reserved seats held at the Pearson VUE centers will be released. After that date, it will be harder for candidates to reserve a seat at their preferred site. Seats in individual cities are limited and are assigned on a first-come, first-served basis. ABOG will not refund any portion of the test fee if a candidate is not able to reserve a seat at their preferred testing center.

If special accommodations are required, those requests must be received no later than the close of the application period (February 28) and should be submitted [here](#). It may not be possible to accommodate requests received after that date. See [Appendix C](#) for more information on requests for special accommodations.

The Qualifying Examination will be given on July 21.

## Fees and Deadlines

The following table lists the deadlines and fees for the Qualifying Examination. Policies related to Fees and Refunds can be found [here](#).

### Qualifying Examination: Deadlines

|                          |  |
|--------------------------|--|
| January 3, 2025          | Applications available online  |
| February 14, 2025        | Application deadline with no late fee  |
| February 28, 2025        | No applications accepted after this date   |
| January to February 2025 | Candidates will be notified of approval to take the examination and to make a Pearson VUE Testing Center reservation |
| April 25, 2025           | Last day to reserve seat at Pearson VUE prior to seat block release  |
| July 21, 2025            | Qualifying Examination at testing centers  |

### Qualifying Examination: Fees

|   |                                  |
|---|----------------------------------|
| January 3, 2025, to February 14, 2025   | \$1700                           |
| February 15, 2025, to February 28, 2025 | \$1700 + \$400 late fee = \$2100 |

## Exam Content

The candidate will be expected to demonstrate skills necessary to apply the appropriate knowledge to the management of clinical problems. These skills include:

1. obtaining needed information;
2. interpretation and use of data obtained;
3. selection, instituting, and implementing appropriate care;
4. management of complications; and

## 5. follow-up and continuing care.

The examination consists of 230 single-best answer, multiple-choice questions. Many of the questions are constructed to be thought-provoking and problem-solving. For most questions, all possible answers may be plausible, but only one answer is the most correct. The Qualifying Examination will only be given in English.

Approximately 33% of the questions on the test will be in Obstetrics, 33% in Gynecology, and 33% in Office Practice. The approximate percentage in each domain is shown below.

| <b><u>Obstetrics (33%)</u></b>                                    | <b><u>Gynecology (33%)</u></b> | <b><u>Office Practice (33%)</u></b>       |
|---|--------------------------------|---|
| Preconception/Prenatal/Antenatal Care (4%)                        | Preoperative Evaluation (4%)   | Well-Woman Preventive Care (10%)          |
| Evaluation/Diagnosis of Antenatal Conditions (8%)                 | Perioperative Care (3%)        | Office Management – Medical Problems (4%) |
| Intrapartum Care, Complications, and Obstetrical Procedures (18%) | Surgical Complications (4%)    | Office Management – Gynecology (15%)      |
| Postpartum Care (3%)  | Postoperative Care (8%)        | Office Procedures (4%)                    |
|   | Gynecologic Emergencies (9%)   |   |
|   | Surgical Procedures (5%)       |   |

Common abbreviations that may be used in ABOG Examinations are found in [Appendix D](#). The specific topics covered within these areas that are assessed on the Qualifying Examination are in [Appendix E](#). Within the scope of obstetrics, gynecology, and office practice, candidates may also be assessed in Cross Content.

## Exam Administration

The Qualifying Examination is scheduled to last approximately 3 hours and 45 minutes. Candidates who finish before the full time has elapsed may leave the Pearson VUE Testing Center early, but if they do so, may not return. Candidates will receive information after registering on the [Pearson VUE Testing Center](#) website concerning the location of their examination, as well as the time they must arrive. Candidates will be required to schedule their examination seat reservation with an 8:00 am start time in their time zone and at a Pearson VUE location in the United States or Canada. Requests to take the examination at a Pearson VUE location outside of the US or Canada will be considered if the reason for the request is out of the control of the candidate (e.g., military deployment).

Specific conduct and expectations on day of testing at the Pearson VUE Testing Center can be found [here](#), including the Test Security agreement.

In the event of unforeseen circumstances that may disrupt or cancel your scheduled appointment on the day of testing, Pearson VUE will offer an option to reschedule your appointment within 5 business days of the original date (on or before the Friday of the week of the exam), and will strive to accommodate your preferred location, date, and time – pending availability at a given center. While they will unfortunately not guarantee preferences, Pearson VUE will work with you to find the best alternative within the 5-business day testing window. If the candidate does not take their exam within the required timeframe, the examination fee will not be refunded and will not be credited toward future applications.



## Results and Scoring

The results of the Qualifying Examination will be reported online to each candidate on or before the last Friday in October. We recognize waiting close to 12 weeks for these important results is difficult and the format of the examination creates an expectation for immediate feedback. Please be assured during this post-examination period, extensive quality assurance checks take place to ensure your test result is fair and accurate. For example, content on the exam is re-reviewed to identify potentially flawed questions. If ABOG determines a question with more than one correct answer (or no correct answer) was on the exam, test-takers will not be penalized for that item.

When results are released, ABOG will provide the candidate their scaled test score in addition to the result of “pass” or “fail.” Each candidate, regardless of whether they pass or fail, will be provided with the percent scored in each of the major topic areas. The cut-point for passing the exam is determined using standard setting methodology every 3-5 years and is equated statistically between that time.

In order to release a result, ABOG must receive the Residency Training Affidavit verifying completion of training completed by the current Program Director. Additionally, **if ABOG does not receive notification of residency completion from the Program Director by January 1, 2026, the results of the examination will be voided.**

As part of the application process, the applicant will be required to irrevocably agree that the results of the applicant’s examination may be made available to the Program Director of any residency program in which the applicant may have participated or in which the applicant is currently involved, and/or the American Council of Graduate Medical Education (ACGME) for any and all purposes. The candidate will also be given the opportunity to release their scaled score on the examination to their current Program Director. Furthermore, the applicant will be required to release and agree to indemnify and hold the ABOG and its officers, directors, and employees harmless of and from any and all claims the applicant may have with regard to the effect or impact upon the applicant of the release of the applicant’s examination results to the applicant’s Program Director or the ACGME and waive any rights the applicant may have, if any, to have the examination results maintained in confidence.

For more information, see [Appendix F](#) on Rescores, Appeals, and Requests for Re-Examination.

## **APPENDIX A: DISCLAIMERS**

### **Gender Language**

The American Board of Obstetrics and Gynecology (ABOG) recognizes that patients have diverse gender identities and is striving to use gender-inclusive language in its publications, literature, and other printed and digital materials. In some instances, ABOG uses the word “woman” (and the pronouns “she” and “her”) to describe patients or individuals whose sex assigned at birth was female, whether they identify as female, male, or non-binary. As gender language continues to evolve in the scientific and medical communities, ABOG will periodically reassess this usage and will make appropriate adjustments as necessary. When describing or referencing study populations used in research, ABOG will use the gender terminology reported by the study investigators.

### **Non-Discrimination and Fairness**

The American Board of Obstetrics and Gynecology does not discriminate on the basis of race, color, creed, age, gender, national origin, religion, disability, marital status, parental status, ancestry, sexual orientation, or any other status protected by law. All candidates for certification will be treated in an equitable manner throughout the certification process and judged solely on the criteria determined by the American Board of Obstetrics and Gynecology.

### **Candidate Responsibility**

ABOG does not assume responsibility to contact potential candidates. Each candidate is responsible for initiating the process, completing all applications, submitting required materials by the deadlines, and paying the appropriate fees.

ABOG annually reviews policies and procedures for determining applicant and candidate certification requirements, as well as compliance with these requirements based on industry standards. Candidates must meet the eligibility requirements published in the Bulletin dated for the year in which they are to take the examination, as requirements may change from year to year. The Bulletin is available under the “Bulletins & Dates” tab online at [www.abog.org](http://www.abog.org). It is the candidate’s responsibility to become familiar with all the material contained in the Bulletin, including the information in the Appendices. Each candidate is also responsible for reading all the policies included in the Policies section under the “About ABOG” tab on the ABOG home page.

After a candidate submits an application to ABOG, it is the candidate’s responsibility to inform ABOG of any changes in personal information (email, phone, address, etc.) by updating the information in their profile on their ABOG portal. Because hospital and university email addresses are often closed after the completion of training, candidates should list a personal email address.

## **Candidate Board Status**

### **ABOG Registered Residency Graduate**

After completing or nearing completion of a residency program in Obstetrics and Gynecology accredited by the American Council for Graduate Medical Education (ACGME) or by the Council of the Royal College of Physicians and Surgeons of Canada (CRCPSC) and meeting all of the requirements listed in the Bulletin, a physician may complete an application to begin the certification process. When and if the Board determines that they have fulfilled the requirements to take the Qualifying Examination, that person becomes a “Registered Residency Graduate.” The term “Board Eligible” is not used or recognized by ABOG.

### **Active Candidate**

A physician achieves “Active Candidate” status by passing the ABOG Qualifying Examination. To maintain Active Candidate status, the candidate must fulfill all of the requirements for admission to the Certifying Examination and may not have exceeded the limitations to admissibility for the Certifying Examination.

All candidates must achieve board certification within eight years of the completion of their training. Training in an ACGME-accredited residency or fellowship does not count toward the 8-year limit. Participation in other fellowships, graduate education programs, etc. do not extend the 8-year limit. Physicians who fail to become certified within eight years will be required to complete a minimum of six months of supervised practice at a hospital affiliated with an ACGME-accredited training program to regain eligibility to apply for the Qualifying Examination. For additional information on regaining eligibility, please see the [Policy on Regaining Eligibility for Initial Certification](#).

## **APPENDIX B: DISQUALIFICATION FROM THE QUALIFYING EXAMINATION**

If a candidate is found to be involved in litigation or investigation regarding ethical or moral issues, the application will be reviewed. ABOG may defer a decision for entry into the examination to gain further information.

If the candidate has one or more licenses to practice medicine in any US state or Canadian province, each license may not be restricted, suspended, revoked, or on probation. Any restrictions or conditions placed on a license, regardless of whether the limits deal specifically with patient care, will disqualify the physician from entry to the Qualifying Examination. Such restrictions and conditions include any provisions requiring the physician to complete additional training and/or practice in a specified manner.

Falsification of any of the submitted data or evidence of other egregious ethical, moral, or professional misbehavior may result in a deferral of a candidate's application for a minimum three years. The candidate must then meet all eligibility requirements in effect at the end of the deferred period.

When the Board rules an applicant not admissible to the Qualifying Examination, a new application and application fee must be submitted after the cause of the inadmissibility has been resolved.

## **APPENDIX C: REQUESTS FOR ACCOMMODATIONS**

### **Candidate Disability**

The American Board of Obstetrics & Gynecology, Inc. (ABOG or Board) provides reasonable accommodations in accordance with the Americans with Disabilities Act (ADA) as amended by the ADA Amendments Act of 2013 (ADAAA) (collectively the ADA) and, therefore, will provide or allow the use of necessary auxiliary aids, services, or testing conditions that do not fundamentally alter the measurement of the skills or knowledge the Board assessment program and examination is intended to test. Candidates must indicate through the examination application if special testing accommodations under the ADA are needed. Accommodations will only be considered with appropriate documentation. In order to implement this policy, notification of the need for special testing circumstances must be submitted in writing to ABOG by a candidate at the time of application. This deadline is necessary in order to allow the Board to request the required documentation, to review the records and to verify the disability, if necessary.

The ADA defines a person with a disability as someone with a physical or mental impairment that substantially limits one or more major life activities such as walking, standing, seeing, hearing, eating, sleeping, speaking, breathing, learning, reading, concentrating, thinking, communicating, or working.

The purpose of accommodations is to provide equal access to ABOG examinations for all individuals. Accommodations offset the identified functional limitation so that the impact of impairment is minimized by means of an auxiliary aid or an adjustment to the testing procedure. Functional limitation refers to the aspects of a disability that interfere with an individual's ability to function in some capacity on a regular and continuing basis.

The purpose of documentation is to validate that an applicant for test accommodations is a disabled individual as defined by the ADA and to provide guidance in determining effective accommodations. Comprehensive information by a qualified professional is necessary to allow ABOG to understand the nature and extent of the applicant's disability and the resulting functional impairment that limits access to its examinations. It is essential that an applicant's documentation provide a clear explanation of the functional impairment and a rationale for the requested accommodation.

No candidate shall be offered an accommodation that would compromise the ABOG examination's ability to test accurately the skills and knowledge it purports to measure, and no auxiliary aid or service will be provided which will fundamentally alter the examination or will result in an undue burden to ABOG.

ABOG shall not exclude any candidate from examination solely because of a disability if ABOG is provided with notice of the disability in time to permit ABOG to make such adjustments in the examination as are reasonably necessary to accommodate the disability. The candidate must provide sufficient documentation to permit ABOG to verify the existence, nature, and extent of the disability. The documentation must specify the requirements or accommodations determined to be necessary to overcome or compensate for the disability. Also, the candidate must supply any additional information ABOG may subsequently request in a timely manner.

If any of the requirements cannot reasonably be provided, ABOG will notify the candidate and will indicate those alternative accommodations which ABOG determines to be appropriate in consideration of the disability claimed and documented, and the integrity of the examination.

If the candidate fails to notify ABOG of a disability at the time of application and fails to achieve a passing grade, that candidate may not appeal the results of the examination but shall be entitled to sit for the next regularly scheduled written examination but must pay a new application and examination fee. If a candidate claims that their examination results were adversely affected by illness, injury, or other temporary physical impairment at the time of the examination, that candidate may not appeal the results of the examination. However, if the candidate provides sufficient evidence of such illness, injury, or impairment, they shall be entitled to sit for the next regularly scheduled certifying examination but must pay a new application and examination fee.

## **Lactation Accommodations**

Candidates who are lactating may request a 30-minute break and extension of their examination if they notify the ABOG office no later than the close of the application period and schedule at a Pearson VUE Testing Center by the same date. Most Pearson VUE Testing Centers have only one room that is available for breast pumping, so candidates are encouraged to make their reservations as soon as they receive approval for the test as these rooms will be assigned on a first-come, first-served basis. If a candidate requests extra time for lactation, ***they must schedule their testing site through the Pearson VUE accommodations department after contacting ABOG. If no seat is available at the closest center, and they have requested extra time, they will have to travel to an available location to sit for the examination.*** As Pearson VUE testing centers have limited lactation facilities, ABOG cannot guarantee that the candidate will be able to schedule at their preferred testing center.

## APPENDIX D: APPROVED ABBREVIATIONS FOR EXAMINATIONS

|           |  |
|-----------|--|
| 2D        | 2-dimensional  |
| 3D        | 3-dimensional  |
| 17-OHP    | 17-hydroxyprogesterone                                     |
| aCGH      | Array comparative genomic hybridization                    |
| ACTH      | Adrenocorticotrophic hormone                               |
| AFI       | Amniotic fluid index                                       |
| AFP       | Alpha-fetoprotein  |
| AGC       | Atypical glandular cells                                   |
| AIS       | Adenocarcinoma in situ                                     |
| ALT       | Alanine aminotransaminase                                  |
| AMA       | Advanced maternal age                                      |
| AMH       | Antimullerian hormone                                      |
| ANC       | Absolute neutrophil count                                  |
| APS       | Antiphospholipid antibody syndrome                         |
| ARDS      | Acute respiratory distress syndrome                        |
| AROM      | Artificial rupture of membranes                            |
| ART       | Antiretroviral therapy or Assisted reproductive technology |
| ASA score | American Society of Anesthesiologists score                |
| ASC       | Abdominal sacrocolpopexy                                   |
| ASCUS     | Atypical cells of undetermined significance                |
| ASRM      | American Society for Reproductive Medicine                 |
| AST       | Aspartate aminotransaminase                                |
| ATFP      | Arcus tendineus fascia pelvis                              |
| AUB       | Abnormal uterine bleeding                                  |
| AZF       | Azoospermia factor   |
| BEP       | Bleomycin, etoposide, cisplatin                            |
| BSO       | Bilateral salpingo-oophorectomy                            |
| BTL       | Bilateral tubal ligation                                   |
| BMI       | Body mass index  |
| BUN       | Blood urea nitrogen  |
| Cm        | Centimeter   |
| CA125     | Cancer antigen 125   |
| CBAVD     | Congenital bilateral absence of the vas deferens           |
| CBC       | Complete blood count                                       |
| CD4       | Cluster of differentiation 4                               |
| CEA       | Carcinoembryonic antigen                                   |
| CI        | Confidence interval  |
| CIN       | Cervical intraepithelial neoplasia                         |
| CMV       | Cytomegalovirus  |
| CNS       | Central nervous system                                     |
| COC       | Combined oral contraceptive                                |
| CPR       | Cardiopulmonary resuscitation                              |
| CT        | Computerized tomography                                    |
| CTA       | Computerized tomography angiography                        |
| CTLA-4    | Cytotoxic T lymphocyte-associated antigen 4                |
| CVS       | Chorionic villus sampling                                  |
| dMMR      | Deficient mismatch repair                                  |
| D & C     | Dilatation and curettage                                   |
| D & E     | Dilatation and evacuation                                  |
| DEXA      | Dual-energy x-ray absorptiometry                           |
| DHEA      | Dehydroepiandrosterone                                     |
| DHEAS     | Dehydroepiandrosterone sulfate                             |
| DIC       | Disseminated intravascular coagulopathy                    |

|         |   |
|---------|---|
| DKA     | Diabetic ketoacidosis   |
| DM      | Diabetes mellitus   |
| DMSO    | Dimethyl sulfoxide  |
| DNA     | Deoxyribonucleic acid   |
| DSD     | Differences of sexual development                                 |
| DVP     | Deepest vertical pocket   |
| DVT     | Deep vein thrombosis  |
| EAS     | External anal sphincter   |
| EBL     | Estimated blood loss  |
| ECC     | Endocervical curettage  |
| ECMO    | Extracorporeal membrane oxygenation                               |
| EGA     | Estimated gestational age   |
| EIN     | Endometrial intraepithelial neoplasia                             |
| ELISA   | Enzyme-linked immunosorbent assay                                 |
| EKG/ECG | Electrocardiogram   |
| EMA-CO  | Etoposide, methotrexate, actinomycin D-cyclophosphamide, Oncovin® |
| EMB     | Endometrial biopsy  |
| EFW     | Estimated fetal weight  |
| ER      | Estrogen receptor   |
| ERAS    | Enhanced recovery after surgery                                   |
| ESHRE   | European Society of Human Reproduction and Embryology             |
| FDA     | Food and Drug Administration                                      |
| FENa    | Fractional excretion of sodium                                    |
| FFP     | Fresh frozen plasma   |
| FGR     | Fetal growth restriction  |
| FHR     | Fetal heart rate  |
| FHT     | Fetal heart tones   |
| FIGO    | International Federation of Gynecology and Obstetrics             |
| FISH    | Fluorescence in situ hybridization                                |
| FSH     | Follicle-stimulating hormone                                      |
| g       | Gram  |
| GBS     | Group B streptococcus   |
| G-CSF   | Granulocyte colony-stimulating factor                             |
| GDM     | Gestational diabetes mellitus                                     |
| GIFT    | Gamete intrafallopian transfer                                    |
| GnRH    | Gonadotropin-releasing hormone                                    |
| GOG     | Gynecologic Oncology Group  |
| GTD     | Gestational trophoblastic disease                                 |
| GTN     | Gestational trophoblastic neoplasia                               |
| HbA1c   | Hemoglobin A1c  |
| HELLP   | Hemolysis, elevated liver function tests, low platelet count      |
| HCG     | Human chorionic gonadotropin                                      |
| HIV     | Human immunodeficiency virus                                      |
| hMG     | Human menopausal gonadotropin                                     |
| HNPCC   | Hereditary nonpolyposis colorectal cancer                         |
| HPO     | Hypothalamic-pituitary-ovarian                                    |
| HPV     | Human papillomavirus  |
| HRT     | Hormone replacement therapy                                       |
| HSG     | Hysterosalpingogram   |
| HSIL    | High-grade squamous intraepithelial lesion                        |
| HSV     | Herpes simplex virus  |
| IAS     | Internal anal sphincter   |
| IC/BPS  | Interstitial cystitis/Bladder pain syndrome                       |
| ICSI    | Intracytoplasmic sperm injection                                  |
| ICU     | Intensive care unit   |
| IgG     | Immunoglobulin G  |



|           |   |
|-----------|---|
| IgM       | Immunoglobulin M  |
| IM        | Intramuscular   |
| INR       | International normalized ratio  |
| IPG       | Implantable pulse generator   |
| IUD       | Intrauterine device   |
| IUFD      | Intrauterine fetal death  |
| IUI       | Intrauterine insemination   |
| IUP       | Intrauterine pregnancy  |
| IV        | Intravenous   |
| IVF       | In vitro fertilization  |
| IVIG      | Intravenous immunoglobulin  |
| kg        | Kilogram  |
| KUB       | Kidney, ureter, bladder   |
| L & D     | Labor and delivery  |
| LARC      | Long-acting reversible contraception                                    |
| LAVH      | Laparoscopic-assisted vaginal hysterectomy                              |
| LDH       | Lactate dehydrogenase   |
| LEEP      | Loop electrosurgical excision procedure                                 |
| LGA       | Large for gestational age   |
| LGBTQIA   | Lesbian gay bisexual transgender queer intersex asexual                 |
| LFT       | Liver function test   |
| LH        | Luteinizing hormone   |
| LMP       | Last menstrual period   |
| LMWH      | Low-molecular-weight heparin  |
| LSIL      | Low-grade squamous intraepithelial lesion                               |
| LVSI      | Lymphovascular space invasion   |
| mL        | Milliliter  |
| mTOR      | Mammalian target of rapamycin   |
| MCA       | Middle cerebral artery  |
| MESA      | Microsurgical epididymal sperm aspiration                               |
| MIS       | Minimally invasive surgery  |
| MRI       | Magnetic resonance imaging  |
| MRKH      | Mayer-Rokitansky-Küster-Hauser  |
| MSAFP     | Maternal serum alpha-fetoprotein  |
| MSI-H, -L | Microsatellite instability-high, -low                                   |
| MTP       | Massive transfusion protocol  |
| MURCS     | Müllerian duct aplasia, renal aplasia, cervicothoracic somite dysplasia |
| NAAT      | Nucleic-acid amplification test   |
| NGS       | Next-generation sequencing  |
| NICU      | Neonatal intensive care unit  |
| NIPT      | Noninvasive prenatal testing  |
| NPO       | Nil per os  |
| NSAID     | Nonsteroidal anti-inflammatory drug                                     |
| OAB       | Overactive bladder  |
| OASIS     | Obstetric anal sphincter injuries                                       |
| OHSS      | Ovarian hyperstimulation syndrome                                       |
| OHVIRA    | Obstructed hemivagina ipsilateral renal agenesis                        |
| PACU      | Postanesthesia care unit  |
| PALND     | Para-aortic lymph node dissection                                       |
| PAP       | Papanicolaou smear  |
| PARP      | Poly adenosine diphosphate-ribose polymerase                            |
| PCOS      | Polycystic ovarian syndrome   |
| PCR       | Polymerase chain reaction   |
| PD-1      | Programmed cell death protein 1   |
| PD-L1     | Programmed cell death ligand 1  |
| PESA      | Percutaneous epididymal sperm aspiration                                |

|             |   |
|-------------|---|
| PET         | Positron emission tomography  |
| PFMT        | Pelvic floor muscle therapy   |
| PFPT        | Pelvic floor physical therapy   |
| PGT-A       | Preimplantation genetic testing for aneuploidy  |
| PGT-M       | Preimplantation genetic testing for monogenic disorder                                      |
| PGT-SR      | Preimplantation genetic testing for structural rearrangements                               |
| PLND        | Pelvic lymph node dissection  |
| PNE         | Peripheral nerve evaluation   |
| POP         | Pelvic organ prolapse   |
| POP-Q       | Pelvic organ prolapse quantification system   |
| PPH         | Postpartum hemorrhage   |
| PR          | Progesterone receptor   |
| PROM        | Premature rupture of membranes  |
| PT          | Prothrombin time  |
| PTT         | Partial thromboplastin time   |
| PPROM       | Preterm premature rupture of membranes  |
| PTNS        | Posterior tibial nerve stimulation  |
| PUBS        | Percutaneous umbilical blood sampling   |
| PUPPP       | Pruritic urticarial papules and plaques of pregnancy  |
| PVR         | Postvoid residual   |
| RAIR        | Rectoanal inhibitory reflex   |
| RBC         | Red blood cell  |
| RCT         | Randomized controlled trial   |
| RNA         | Ribonucleic acid  |
| RPL         | Recurrent pregnancy loss  |
| RPR         | Rapid plasma reagin   |
| SBO         | Small bowel obstruction   |
| S/D (ratio) | Systolic/diastolic ratio  |
| SGA         | Small for gestational age   |
| SHBG        | Sex hormone-binding globulin  |
| SLND        | Sentinel lymph node dissection  |
| SNM         | Sacral neuromodulation  |
| SNP         | Single-nucleotide polymorphism  |
| SO          | Salpingo-oophorectomy: preceded by R (right) or L (left) or unilateral (U)                  |
| SROM        | Spontaneous rupture of membranes  |
| SSLF        | Sacrospinous ligament fixation  |
| STI         | Sexually transmitted infection  |
| SUI         | Stress urinary incontinence   |
| SS-A        | Sjogren syndrome A  |
| SS-B        | Sjogren syndrome B  |
| SVD         | Spontaneous vaginal delivery  |
| T1DM        | Type I diabetes mellitus  |
| T2DM        | Type II diabetes mellitus   |
| TAH         | Total abdominal hysterectomy  |
| TCGA        | The Cancer Genome Atlas   |
| TESA        | Testicular sperm aspiration   |
| TESE        | Testicular sperm extraction   |
| TLH         | Total laparoscopic hysterectomy   |
| TNF         | Tumor necrosis factor   |
| TOLAC       | Trial of labor after cesarean   |
| TOT         | Transobturator tape   |
| TSH         | Thyroid-stimulating hormone   |
| TRALI       | Transfusion-related acute lung injury   |
| TTTS        | Twin-twin transfusion syndrome  |
| TUNEL       | Terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate-nick end labelling |
| TVH         | Total vaginal hysterectomy  |

|      |  |
|------|--|
| TVS  | Transvaginal sonography                      |
| TVT  | Tension-free vaginal tape                    |
| UAE  | Uterine artery embolization                  |
| USLF | Uterosacral ligament fixation                |
| UTI  | Urinary tract infection                      |
| VAC  | Vincristine, actinomycin-D, cyclophosphamide |
| VAIN | Vaginal intraepithelial neoplasia            |
| VBAC | Vaginal birth after cesarean delivery        |
| VCUG | Voiding cystourethrography                   |
| VDRL | Venereal disease research laboratory         |
| VEGF | Vascular endothelial growth factor           |
| VIN  | Vulvar intraepithelial neoplasia             |
| VLPP | Valsalva leak point pressure                 |
| V/Q  | Ventilation/Perfusion                        |
| VTE  | Venous thromboembolism                       |
| VVF  | Vesicovaginal fistula                        |
| WBC  | White blood cell                             |
| WES  | Whole exome sequencing                       |
| WHO  | World Health Organization                    |
| ZIFT | Zygote intrafallopian transfer               |

## APPENDIX E: SPECIALTY QUALIFYING EXAMINATION TOPICS

### Obstetrics

|  |
|--|
| <b>Preconception/Prenatal/Antenatal Care</b>   |
| <b><i>Provide Preconception, Prenatal, and Antenatal Care</i></b>  |
| Apply knowledge of pregnancy physiology to differentiate physiological changes from pathological conditions  |
| Provide management, counseling, and testing for routine prenatal care (e.g., vaccinations, abnormal laboratory results, routine sonography, postpartum contraception)  |
| Evaluate, diagnose, and provide initial management of co-existent medical conditions during pregnancy and preconception (e.g., cardiovascular, pulmonary, renal, gastrointestinal including liver disease, hematologic, endocrine, psychiatric, autoimmune, neoplastic, dermatologic, neurologic, obesity) |
| Provide patient counseling regarding options, risks, and benefits of genetic testing (e.g., maternal carrier screening, aneuploidy screening, diagnostic testing)  |
| <b>Evaluation/Diagnosis of Antenatal Conditions</b>  |
| <b><i>Evaluate, Diagnose, and Manage Preconception/Antenatal Conditions with Predominantly Fetal Effects</i></b>   |
| Select, perform, and interpret antepartum fetal assessment and manage associated abnormalities (e.g., biophysical profile, contraction stress test, nonstress test, vibroacoustic stimulation)   |
| Evaluate, diagnose, and manage preterm labor/delivery and those at risk  |
| Evaluate, diagnose, and manage fetal anomaly identified during standard second-trimester ultrasound examination  |
| Evaluate, diagnose, and manage multifetal gestation  |
| Evaluate, diagnose, and manage fetal growth abnormalities (e.g., fetal growth restriction, macrosomia)   |
| Evaluate, diagnose, and manage postterm gestation  |
| Evaluate, diagnose, and manage second- and third-trimester stillbirth  |
| <b><i>Evaluate, Diagnose, and Manage Preconception/Antenatal Predominantly Maternal Conditions</i></b>   |
| Evaluate, diagnose, and manage common first-trimester complications (e.g., first-trimester bleeding, miscarriage, uterine incarceration)   |
| Evaluate, diagnose, and manage second-trimester complications (e.g., cervical insufficiency, PPROM, second-trimester miscarriage/demise)   |
| Evaluate, diagnose, and manage hypertensive disorders of pregnancy (e.g., chronic hypertension, gestational HTN, pre-eclampsia, eclampsia)   |
| Evaluate, diagnose, and manage pregestational and gestational diabetes   |
| Evaluate, diagnose, and manage medical disorders unique to pregnancy (e.g., hyperemesis, cholestasis of pregnancy, acute fatty liver of pregnancy, peripartum cardiomyopathy, PUPPP/PEP, pemphigoid gestationis, isoimmunization)  |
| Evaluate, diagnose, and manage antepartum infections (e.g., HIV, varicella, parvovirus, syphilis, TORCH, COVID-19, pyelonephritis)   |
| Evaluate, diagnose, and manage surgical conditions and nonobstetrical emergencies during pregnancy (e.g., acute abdomen, adnexal masses, renal stone, trauma)  |
| <b>Intrapartum Care, Complications, and Obstetrical Procedures</b>   |
| <b><i>Provide General Intrapartum Care</i></b>   |
| Provide operative vaginal delivery (e.g., forceps, vacuum)   |
| Provide cesarean delivery and manage intraoperative complications (e.g., GU injury, GI injury, uterine artery laceration, hysterotomy extension, inadequate operating space)   |
| Evaluate, diagnose, and manage obstetrical lacerations and associated complications  |
| Counsel patients on analgesia options and manage intrapartum pain  |

|   |
|---|
| Evaluate, diagnose, and initially manage neonates in need of resuscitation; counsel about and/or perform circumcision   |
| Manage induction or augmentation of labor   |
| Provide interventions to reduce perioperative complications (e.g., infection, thromboembolism, blood loss, fetal injury)  |
| <b><i>Evaluate, Diagnose, and Manage Intrapartum Conditions</i></b>   |
| Labor abnormalities (e.g., dystocia, PROM, cord problems, abnormal position or presentation)  |
| Management of postpartum hemorrhage and uterine inversion (e.g., uterine atony, retained placenta, uterine inversion, medical and surgical options)                             |
| Placental abnormalities (e.g., placenta previa, vasa previa, placenta accreta spectrum, placental abruption)  |
| Acute maternal decompensation (e.g., amniotic fluid embolism, sepsis, shock, high spinal analgesia, pulmonary embolism)   |
| Fetal heart rate abnormalities  |
| Prior cesarean delivery (e.g., TOLAC, VBAC, uterine rupture)  |
| Manage infection in labor (e.g., chorioamnionitis, Group B streptococcus, HSV, HIV, HBV, HCV)   |
| <b><i>Evaluate, Diagnose, and Manage Intrapartum Conditions: Procedures</i></b>   |
| Vaginal delivery  |
| Management of singleton breech fetus (e.g., vaginal breech delivery or external cephalic version)   |
| Vaginal delivery of twin gestation  |
| Shoulder dystocia maneuvers   |
| Peripartum hysterectomy   |
| Cervical cerclage   |
| Immediate postpartum contraception (e.g., sterilization or IUD insertion)   |
| Transvaginal basic obstetric first- or second-trimester ultrasound examination  |
| Abdominal basic obstetric second- or third trimester ultrasound examination   |
| <b><i>Postpartum Care</i></b>   |
| <b><i>Provide General Postpartum Care</i></b>   |
| Provide routine care (e.g., pain management, wound inspection, sleep assessment, social support assessment)   |
| Evaluate, diagnose, and manage postpartum complications (e.g., vulvar and vaginal hematoma, endometritis, surgical site infections; hemorrhoids)                                |
| Evaluate and manage common medical and obstetrical complications or conditions (e.g., gestational diabetes, hypertension, depression, thyroid disorders, psychiatric disorders) |
| Evaluate, diagnose, and manage lactation and breastfeeding complications (e.g., puerperal mastitis)   |

## Gynecology

|   |
|---|
| <b><i>Preoperative Evaluation</i></b>   |
| <b><i>Provide General Preoperative Evaluation</i></b>   |
| Perform informed consent (e.g., surgery risks, benefits, & alternatives; surgical route; blood transfusion risks; ovarian preservation; anesthesia complications) |
| Perform preoperative evaluation and ensure patient candidacy for planned surgery  |
| Identify, evaluate, and optimize co-existing pertinent medical conditions   |
| <b><i>Perioperative Care</i></b>  |
| <b><i>Perform Perioperative Care</i></b>  |

|  |
|--|
| Provide interventions to reduce perioperative complications (e.g., infection, thromboembolism, blood loss, fires, retained foreign body, wrong surgery site)                     |
| Institute enhanced recovery after surgery (e.g., perioperative pain management, ambulation, feeding)   |
| Communicate with interdisciplinary team members to provide appropriate anesthesia and positioning  |
| <b>Surgical Complications</b>  |
| <b><i>Provide General Intraoperative Care</i></b>  |
| Apply knowledge of female pelvic anatomy and disease pathology to reduce intraoperative complications  |
| Evaluate, diagnose, and manage intraoperative hemorrhage, including vascular injuries  |
| Evaluate, diagnose, and initially manage GI tract injuries   |
| Evaluate, diagnose, and initially manage GU tract injuries   |
| Evaluate, diagnose, and initially manage intraoperative findings of gynecological malignancy   |
| <b>Postoperative Care</b>  |
| <b><i>Evaluate, Diagnose, and Manage Postoperative Care</i></b>  |
| Provide routine postoperative care   |
| Urinary tract injury / complications (e.g., disruption or obstruction, infection, retention)   |
| Wound complications (e.g., infection, disruption, necrotizing fasciitis)   |
| Vascular injury / complications (e.g., postoperative hemorrhage or hematoma, VTE, transfusion reaction)  |
| Nerve injury   |
| GI tract injury / complications (e.g., delayed bowel injury, ileus, SBO, infection, postoperative nausea and vomiting)   |
| Pulmonary complications (e.g., pulmonary embolism, infection, asthma, volume overload)   |
| <b>Gynecologic Emergencies</b>   |
| <b><i>Evaluate, Diagnose, and Manage Gynecologic Emergencies</i></b>   |
| Adnexal emergency (e.g., PID/TOA, adnexal torsion, ruptured ovarian cysts)   |
| Vulvar emergency (e.g., Bartholin gland duct abscess, vulvar abscess, fasciitis, straddle injury, sexual assault)  |
| Ectopic pregnancy and pregnancies of unknown location (e.g., tubal, interstitial, cesarean scar, cervical, ovarian sites)  |
| Acute uterine complications (e.g., heavy abnormal uterine bleeding; leiomyoma prolapse, degeneration, or torsion; hematometra)   |
| Genitourinary emergencies (e.g., renal stone; procidentia with retention or with erosion; urethral diverticulum infection)   |
| <b>Surgical Procedures</b>   |
| <b><i>Perform Minimally Invasive Surgical Procedures</i></b>   |
| Operative hysteroscopy (e.g., myomectomy, polypectomy, endometrial ablation, adhesiolysis)   |
| Minimally invasive hysterectomy (vaginal, laparoscopic, robotic)   |
| Operative laparoscopy (e.g., lysis of adhesions, ovarian cystectomy, salpingectomy, salpingo-oophorectomy, sterilization, ablation or resection of endometriosis, salpingostomy) |
| <b><i>Perform Minor Gynecologic Surgical Procedures</i></b>  |
| Cervical conization and LEEP   |
| Dilation and curettage (not pregnancy related)   |
| Vulvar or vaginal surgery  |
| Diagnostic cystoscopy  |
| <b><i>Perform Major Open Gynecologic Surgical Procedures</i></b>   |
| Abdominal incisions (e.g., Pfannenstiel, Maylard, Cherney, midline vertical; wound debridement; closure options)   |
| Abdominal hysterectomy   |

|  |
|--|
| Abdominal myomectomy   |
| Adnexal surgery (e.g., oophorectomy, cystectomy, salpingectomy, salpingo-oophorectomy, tubal sterilization, salpingostomy, endometriosis/endometrioma) |
| <b>Perform Surgeries for Pelvic Floor Disorders (e.g., prolapse, incontinence)</b>   |
| Diagnostic and operative cystoscopy and urethroscopy   |
| Surgical repair of urinary incontinence (e.g., Burch colposuspension, tension-free vaginal tape, transobturator tape sling)                            |
| Vesicovaginal fistula repair   |
| Vaginal prolapse repair (e.g., anterior colporrhaphy, posterior colporrhaphy, perineorrhaphy)  |
| Apical suspension (e.g., uterosacral ligament suspension, sacrospinous ligament fixation, McCall culdoplasty)  |
| Colpocleisis   |

## Office Practice

|  |
|--|
| <b>Well-Woman Preventative Care</b>  |
| <b>Provide Routine Care</b>  |
| Perform age-appropriate preventive health screening and immunization (e.g., pediatric, adolescent, reproductive-age, perimenopausal, geriatric groups) |
| Perform universal screening of mental health, substance use disorder, intimate partner violence, social health determinants                            |
| Evaluate and manage at-risk patients and recommend genetic screening and cancer preventive measures  |
| Counsel and promote wellness (e.g., physical activity, stress management, nicotine cessation, sleep health, bone health)                               |
| Provide reproductive counseling (individual reproductive priorities, optimize fertility and pre-pregnancy health)                                      |
| Counsel and promote sexual health and wellness and healthy relationships   |
| Counsel regarding family planning methods, contraception, sterilization, abortion options  |
| Educate and counsel regarding diet and nutrition for promotion of health, weight management, disease prevention, and treatment of chronic conditions   |
| <b>Provide Care for Patients with Unique Obstetrical or Gynecologic Needs</b>  |
| Pediatric and adolescent patients  |
| LGBTQIA patients (e.g., acknowledge gender identity, hormone suppression or replacement, gender affirming surgeries, preventive care)                  |
| Intimate partner violence and sexual assault   |
| Psychiatric disorders (depression, anxiety, substance use disorder, eating disorder)   |
| Patients with compromised health (e.g., mental disability, physical disability, immunocompromised patient, HIV infection)                              |
| <b>Office Management - Medical Problems</b>  |
| <b>Evaluate and Initiate Management of Primary Care Problems</b>   |
| Breast disorders   |
| Cardiovascular disease risk factors (e.g., chronic hypertension, hyperlipidemia, obesity)  |
| Gastrointestinal disease   |
| Musculoskeletal disorders (e.g., low back pain, abdominal wall hernia)   |
| Headaches  |
| Asthma   |

|   |
|---|
| Osteoporosis and osteopenia   |
| <b>Office Management - Gynecology</b>   |
| <b><i>Perform General Office Gynecology Care</i></b>  |
| Evaluate, diagnose, and initiate management of infertility and recurrent pregnancy loss   |
| Evaluate, diagnose, and manage menopause (e.g., vasomotor symptoms, genitourinary syndrome of menopause)  |
| Evaluate, diagnose, and initiate management for sexual development disorders (e.g., structural, chromosomal, including transition to adult OB GYN care)                   |
| Evaluate and manage abnormal cervical cancer screening results (colposcopy, biopsy, LEEP, etc.)   |
| Evaluate, diagnose, and manage adnexal abnormalities (e.g., simple and complex masses, mittelschmerz)   |
| Evaluate, diagnose, and manage urinary tract infections   |
| Evaluate, diagnose, and manage chronic pain conditions (e.g., vulvodynia, dyspareunia, interstitial cystitis, irritable bowel syndrome)                                   |
| Evaluate, diagnose, and manage endometriosis  |
| Evaluate, diagnose, and manage female sexual dysfunction (e.g., desire, arousal, orgasm)  |
| Provide and manage contraception (e.g., options, side effects or complications, emergency contraception, LARC, noncontraceptive benefits)                                 |
| <b><i>Evaluate, Diagnose, and Manage Endocrine Disorders</i></b>  |
| Androgen excess (e.g., polycystic ovary syndrome, ovarian tumor, Cushing disease/syndrome)  |
| Hyperprolactinemia and galactorrhea   |
| Disorders of puberty  |
| Diabetes mellitus   |
| Thyroid disease   |
| <b><i>Evaluate, Diagnose, and Manage Disorders of Menstruation</i></b>  |
| Primary amenorrhea  |
| Secondary amenorrhea  |
| Abnormal uterine bleeding, (endometrial biopsy, hysteroscopy)   |
| Premenstrual dysphoric disorder   |
| Dysmenorrhea  |
| <b><i>Evaluate, Diagnose, and Manage Vulvovaginal Conditions</i></b>  |
| Vaginal discharge (e.g., fungal, bacterial vaginosis, desquamative inflammatory vaginitis)  |
| Sexually transmitted infections (e.g., syphilis, gonorrhea, trichomoniasis, chlamydial infection, chancroid, pubic lice, molluscum contagiosum, or HPV or HSV infections) |
| Vulvar intraepithelial neoplasia / Vaginal intraepithelial neoplasia  |
| Vulvar skin conditions (e.g., contact dermatitis, lichen simplex chronicus, lichen sclerosis, lichen planus, hidradenitis suppurativa)                                    |
| <b><i>Evaluate, Diagnose, and Manage Structural Uterine Abnormalities</i></b>   |
| Leiomyoma   |
| Endometrial or cervical polyps  |
| Hyperplasia and endometrial intraepithelial neoplasia (EIN)   |
| Adenomyosis   |
| <b><i>Evaluate, Diagnose, and Initiate Management of Incontinence/Pelvic Floor Disorders</i></b>  |
| Urinary incontinence  |
| Fecal incontinence  |
| Pelvic organ prolapse   |



|   |
|---|
| Fistula   |
| <b><i>Evaluate, Diagnose, and Initiate Management for Reproductive Tract Cancer</i></b> |
| Vulvar or vaginal   |
| Cervical  |
| Uterine   |
| Ovarian/ Fallopian Tubes  |
| Gestational Trophoblastic Disease (GTD)   |
| <b>Office Procedures</b>  |
| <b><i>Perform Office-based Procedures</i></b>   |
| Induced medication abortion   |
| Induced abortion procedure  |
| Pessary fitting   |
| Office procedure pain management (e.g., cervical block)                                 |
| Abdominal pelvic ultrasonography  |
| Transvaginal pelvic ultrasonography   |

## Cross Content

|   |
|---|
| <b>Applied basic science, anatomy, pathophysiology, and evidence-based medicine</b>   |
| 1. Apply knowledge of female anatomy and pathophysiology to improve patient outcomes  |
| 2. Apply knowledge of applied basic science (e.g., microbiology, immunology, embryology, pharmacology, genetics) to improve patient outcomes  |
| 3. Apply epidemiology, statistics, and evidence-based medicine to interpret OB GYN literature and improve patient outcomes  |
| <b>Cultural awareness and equitable care</b>  |
| 4. Demonstrate cultural awareness when providing care to a diverse patient population, including but not limited to, gender, age, culture, race, religion, disabilities, and sexual orientation |
| 5. Provide equitable and respectful care that is responsive to a patient's culture  |
| <b>Patient communication (crisis and unexpected situations)</b>   |
| 6. Disclose unexpected, adverse events, or medical errors or unexpected situations  |
| 7. Crisis situations (e.g., substance abuse, intimate partner violence)   |
| <b>ACGME competencies and inter-related skills</b>  |
| 8. Participate in and use systems-based surgical quality improvement processes  |
| 9. Execute timely and accurate debriefs and patient handoffs  |
| 10. Identify fitness for duty among colleagues and intervene as required  |
| 11. Create and maintain a respectful working environment  |
| 12. Provide care with multidisciplinary teams (Systems-based practice)  |
| 13. Participate in continuous quality improvement (Practice-based learning and improvement)   |
| 14. Adhere to standards of care, professional responsibilities, and ethical principles (Professionalism)  |

## **APPENDIX F: RESCORES, APPEALS, AND REQUESTS FOR RE-EXAMINATION**

### **Rescores and Appeals**

Since ABOG utilizes many quality control procedures to ensure exams are scored accurately and there is no record of incorrect scoring at ABOG with any of ABOG's multiple-choice examinations, ABOG does not accept rescore requests. This includes, but is not limited to, rescoring of the exam, review of exam content, reconsideration of a correct response, reconsideration of the passing standard, and/or consideration of the acceptability of testing conditions.

In addition, ABOG does not accept appeals from candidates who seek to challenge the content of the examination, the sufficiency or accuracy of the answers to examination questions, the scoring of the examination, or the cut score used to determine the passing grade for the examination.

A complaint concerning any other matter regarding ABOG examinations should be submitted [here](#).

### **Requests for Re-Examination**

Candidates who are scheduled to take the examination but do not do so, as well as candidates who do not pass the examination and who wish to repeat the examination, must complete a new application on the ABOG website and pay a new fee. It is necessary for each applicant to meet the requirements in effect the year the application is submitted. These requirements can be found in the Bulletin for the year the application is submitted. The re-applicant must complete the application process before the applicable deadline.